Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus
Phase 1CompletedDevelopment Stage
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Nov 1, 2010 โ Mar 1, 2014
About Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus
Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus is a phase 1 stage product being developed by Novartis for Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System. The current trial status is completed. This product is registered under clinical trial identifier NCT01263353. Target conditions include Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01263353 | Phase 1 | Completed |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection๏ผlong-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Lanreotide + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 33 |
| Lutatheraยฎ | Novartis | Pre-clinical | 23 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 49 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 38 |
| Lanreotide autogel | Ipsen | Phase 3 | 74 |